Tarlatamab is a DLL3-directed bispecific T-cell engager approved for extensive-stage small cell lung cancer. This page compares Tarlatamab to other treatments for SCLC, including Lurbinectedin (Zepzelca), Topotecan (Hycamtin), Atezolizumab (Tecentriq), and Durvalumab (Imfinzi). Its novel mechanism of action as a T-cell engager offers a distinct approach compared to traditional chemotherapy or immune checkpoint inhibitors.
Tarlatamab Alternatives: How It Compares to Other SCLC Therapies
Hipa.ai Research · Source: ClinicalTrials.gov / AACT · Last updated: Limited data · 0/6 curated
Source: ClinicalTrials.gov via AACT · Hipa.ai, 2026-05-07Download chart as PNG
The competitive landscape includes older treatments like Topotecan (Hycamtin), approved in 1996, and Atezolizumab (Tecentriq), approved in 2016. Tarlatamab was recently approved in 2024, while Zg006 is still in Phase 3, potentially 1-2 years behind.
Quick comparison table
| Drug | Class | Approved indications | Dosing | Year approved | Lead pivotal endpoint | Annual cost (rough) |
|---|---|---|---|---|---|---|
| Tarlatamab (Imdelltra) | DLL3-directed bispecific T-cell engager | Extensive-stage small cell lung cancer | 1 mg IV on Cycle 1 Day 1, followed by 10 mg IV on Cycle 1 Days 8 and 15, then 10 mg IV every 2 weeks thereafter | 2024 | Overall Survival (OS): 13.6months @ median | $782k |
| Topotecan (Hycamtin) | Topoisomerase I inhibitor | Ovarian cancer, Small cell lung cancer, Cervical cancer | 1.5 mg/m2 IV daily for 5 consecutive days every 21 days (ovarian and small cell lung cancer); 2.3 mg/m2 orally once daily for 5 consecutive days every 21 days (small cell lung cancer); 0.75 mg/m2 IV daily for 3 consecutive days every 21 days with cisplatin (cervical cancer) | 1998 | — | — |
| Atezolizumab (Tecentriq) | PD-L1 inhibitor | Non-small cell lung cancer, Small cell lung cancer, Hepatocellular carcinoma, +2 more | 1200 mg intravenously every 3 weeks | 2019 | overall survival: 13.8months @ median | $191k |
| Durvalumab (Imfinzi) | PD-L1 inhibitor | bladder cancer, non-small cell lung cancer, small cell lung cancer, +4 more | 1500 mg intravenously every 3 to 4 weeks | 2020 | Progression-Free Survival: 16.8months @ median | — |
| Lurbinectedin (Zepzelca) | Alkylating drug | Metastatic small cell lung cancer, Extensive-stage small cell lung cancer | 3.2 mg/m2 by intravenous infusion over 60 minutes every 21 days | 2020 | 35.2% | $225k |
| Zg006 | — | — | — | Pipeline | — | — |
Cost estimates are list-price approximations and do not reflect rebates, formulary tier, or out-of-pocket costs after benefits. The class-typical lead-pivotal endpoint here is Objective Response Rate (ORR); cells render each drug's actual pivotal endpoint, which may differ. The "Year approved" column shows the FDA approval year for small cell lung cancer specifically — drugs approved for other indications first appear with their this-indication date, or as Pipeline if not yet approved for this indication. Cross-trial comparisons can mislead — head-to-head Phase-3 data (when present) is below.
Tarlatamab vs Lurbinectedin (Zepzelca)
The pivotal head-to-head evidence comes from a head-to-head Phase-3 trial (NCT05740566) enrolling 509 participants, primary completion 2025-01.
Overall Survival (OS): Standard of Care (SOC) 8.3 months; Tarlatamab 1 mg to 10 mg Q2W 13.6 months
Source: ClinicalTrials.gov via AACT — pulled directly from the trial's posted results. View the full trial record.
Tarlatamab vs Topotecan (Hycamtin)
The pivotal head-to-head evidence comes from a head-to-head Phase-3 trial (NCT05740566) enrolling 509 participants, primary completion 2025-01.
Overall Survival (OS): Standard of Care (SOC) 8.3 months; Tarlatamab 1 mg to 10 mg Q2W 13.6 months
Source: ClinicalTrials.gov via AACT — pulled directly from the trial's posted results. View the full trial record.
Tarlatamab vs Atezolizumab (Tecentriq)
No head-to-head Phase-3 trial directly compares Tarlatamab with Atezolizumab.
In separate pivotal trials, Tarlatamab reported 13.6months Overall Survival (OS) at median (NCT05740566) versus 13.8months overall survival at median for Atezolizumab (NCT02008227).
Cross-trial caveat: the two drugs were tested in different patient populations at different time points. Cross-trial comparisons of response rates can mislead — the only rigorous comparison is a head-to-head randomized trial.
Tarlatamab vs Durvalumab (Imfinzi)
The pivotal head-to-head evidence comes from a head-to-head Phase-3 trial (NCT06211036) enrolling 563 participants, primary completion 2027-07.
Primary-endpoint values for NCT06211036 are not yet posted in the AACT results database.
Source: ClinicalTrials.gov via AACT — pulled directly from the trial's posted results. View the full trial record.
Pipeline alternatives
Among investigational IL-17 / IL-17-related drugs currently in active Phase 3 development is Zg006. The sponsor for Zg006 is currently unknown.
Choosing between Tarlatamab and its alternatives
Clinicians considering treatment options for small cell lung cancer (SCLC) may evaluate Tarlatamab based on its unique mechanism of action. As a DLL3-directed bispecific T-cell engager, Tarlatamab represents a distinct therapeutic approach compared to other available agents. This novel mechanism may be a factor in treatment selection, particularly for patients who have progressed on or are not candidates for therapies with different mechanisms.
Conversely, other established therapies offer different mechanisms and known efficacy profiles that may be preferred in certain clinical situations. Lurbinectedin, an alkylating drug, has demonstrated an objective response rate of 35.2% and is administered as a 3.2 mg/m2 intravenous infusion every 21 days. Topotecan, a topoisomerase I inhibitor, is available in both intravenous and oral formulations, with dosing schedules such as 1.5 mg/m2 IV daily for 5 days or 2.3 mg/m2 orally daily for 5 days, both every 21 days. Immunotherapy options include PD-L1 inhibitors such as Atezolizumab, which has a median overall survival of 13.8 months with 1200 mg intravenous dosing every 3 weeks, and Durvalumab, which has a median progression-free survival of 16.8 months with 1500 mg intravenous dosing every 3 to 4 weeks. These agents offer varying dosing frequencies and established efficacy data, which may influence treatment decisions based on patient characteristics, prior therapies, and tolerability profiles.
This information is for educational purposes and does not constitute medical advice; clinical decisions regarding patient care should always be made by a qualified prescriber.
Sources and methodology
Trial data was pulled from the ClinicalTrials.gov registry via the AACT relational mirror maintained by the Clinical Trials Transformation Initiative. AACT data freshness: .
Head-to-head trials cited on this page:
- NCT05740566: Tarlatamab vs Lurbinectedin · Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
- NCT05740566: Tarlatamab vs Topotecan · Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
- NCT06211036: Tarlatamab vs Durvalumab · Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (…
Cross-trial comparison limitations:drugs without a direct head-to-head trial are compared using each drug's own pivotal trial. These trials enrolled different patient populations at different time points and used different statistical analysis sets. Cross-trial response-rate differences should not be interpreted as proof that one drug is more effective than another.
Related drug pages on Hipa.ai
Not medical advice. This page summarizes publicly-reported clinical trial data for informational purposes. Treatment decisions belong with a qualified prescribing clinician who knows your medical history. Drug approvals, dosing, and safety profiles change over time — always confirm with the current FDA prescribing information.
tarlatamabtarlatamab alternativesalternativescomparisonsmall cell lung cancerdll3-sclctarlatamab vs lurbinectedintarlatamab vs topotecantarlatamab vs atezolizumabtarlatamab vs durvalumabtarlatamab vs zg006